1022091-49-1

Basic information

• Product Name: 5,7-Difluoro-6-bromoquinoline
• Synonyms: 5,7-Difluoro-6-bromoquinoline;6-Bromo-5,7-difluoroquinoline
• CAS NO: 1022091-49-1
• Molecular Formula: C9H4BrF2N
• Molecular Weight: 244.0355664
• EINECS: 1312995-182-4
• Product Categories: Building Blocks;C8 to C10;Chemical Synthesis;Fluorinated Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Heterocyclic Fluorinated Building Blocks;Other Fluorinated Heterocycles;Quinolines;Building Blocks/Intermediates
• Mol File: 1022091-49-1.mol

Chemical Properties

• Melting Point: 87-92℃
• Boiling Point: 288℃
• Flash Point: 128℃
• Appearance: /
• Density: 1.726
• Storage Temp.: 2-8°C
• PKA: 2.05±0.29(Predicted)
• CAS DataBase Reference: 5,7-Difluoro-6-bromoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-Difluoro-6-bromoquinoline(1022091-49-1)
• EPA Substance Registry System: 5,7-Difluoro-6-bromoquinoline(1022091-49-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• RIDADR: UN 3335
• WGK Germany: 1
• Hazardous Substances Data: 1022091-49-1(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 372-39-4 3,5-difluoroaniline 
• 203302-95-8 4-bromo-3,5-difluorophenylamine 
• 56-81-5 glycerol 

Downstream Products

• 1185767-02-5 5,7-difluoroquinoline-6-carbaldehyde 

Relevant articles and documents

Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization

c-Met/HGF signaling pathway plays an important role in cancer progression, and it was considered to be related to poor prognosis and drug resistance. Based on metabolite profiling of (S)-7-fluoro-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyrazin

Quinoline compounds and preparation method thereof, and intermediate, pharmaceutical composition and application of quinoline compounds

The invention discloses quinoline compounds and a preparation method thereof, and an intermediate, a pharmaceutical composition and application of quinoline compounds. The invention provides quinoline compounds disclosed as Formula 1, and pharmaceutically acceptable salts, solvates, metabolites, metabolism precursors or pharmaceutical precursors thereof. The quinoline compounds have favorable inhibitory effects on tyrosine kinase C-Met, and can be used for preparing drugs for prevention, treatment or auxiliary treatment on multiple diseases related to C-Met expression or activity, and especially neoplastic diseases.

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE

The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

HETEROCYCLIC KINASE MODULATORS

The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.